180 Life Sciences Corp. (ATNF)

NASDAQ: ATNF · IEX Real-Time Price · USD
0.970
+0.060 (6.59%)
Jul 7, 2022 1:13 PM EDT - Market open
6.59%
Market Cap 33.12M
Revenue (ttm) n/a
Net Income (ttm) -2.56M
Shares Out 34.14M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 79,070
Open 0.900
Previous Close 0.910
Day's Range 0.900 - 0.970
52-Week Range 0.790 - 11.200
Beta -0.12
Analysts Sell
Price Target 5.10 (+425.8%)
Earnings Date Aug 15, 2022

About ATNF

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under pre... [Read more...]

Industry Biotechnology
Founded 2016
Employees 2
Stock Exchange NASDAQ
Ticker Symbol ATNF
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ATNF stock is "Sell." The 12-month stock price forecast is 5.1, which is an increase of 425.77% from the latest price.

Price Target
$5.1
(425.77% upside)
Analyst Consensus: Sell
Stock Forecasts

News

180 Life Sciences Corp. Issues Letter to Stockholders

PALO ALTO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"), a clinical-stage biotechnology company today released the following let...

Why 180 Life Sciences Shares Are Plunging Today

180 Life Sciences Corp (NASDAQ: ATNF) received a written response from the U.K.'s regulatory agency and U.S. FDA related to questions submitted in a Type C meeting request for anti-TNF treatment, adalim...

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for...

PALO ALTO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of n...

180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prev...

PALO ALTO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of no...

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Result...

PALO ALTO, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of ...

180 Life Sciences Corp. Forms Scientific Advisory Board

PALO ALTO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of n...

180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022

PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of n...

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for...

PALO ALTO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of n...

4 Penny Stocks To Buy For Under $5 Before 2022

You can buy these penny stocks for under $5 but are they worth the risk? The post 4 Penny Stocks To Buy For Under $5 Before 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...

Other symbols: FWBIPTPIXERS

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company's Successful Dupuytren's Phase ...

PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of n...

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytr...

‘Cellular and Molecular Profiling of Dupuytren's Disease: From the Lab to the Clinic' Presented Wednesday, December 1, 2021, at 3pm EST ‘Cellular and Molecular Profiling of Dupuytren's Disease: From the...

180 Life Sciences Corp. Expands Patent Portfolio

New IP Relates to a Method for Treating Chronic Pain or Associated Conditions/Symptoms with Novel Compositions Including Certain Phenyl Substituted Cyclohexenyl Compounds Related to Cannabidiol (CBD) Ne...

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dup...

‘Re-purposing anti-TNF for Dupuytren's Disease' Being Presented Wednesday, December 1, 2021, at 3pm EST ‘Re-purposing anti-TNF for Dupuytren's Disease' Being Presented Wednesday, December 1, 2021, at 3p...

180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer

Highly Accomplished Strategy, Corporate/Business Development, Finance and Operations Executive With 20 Years of Biopharma Experience Highly Accomplished Strategy, Corporate/Business Development, Finance...

180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation a...

PALO ALTO, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of n...

180 Life Sciences Stock Bounces Off Support: What's Next?

180 Life Sciences Corp. (NASDAQ:ATNF) shares are trading higher Monday, although there looks to be no company-evident news to explain the jump in price. The stock was trending on social media sites thro...

180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio

Notice of Allowance Issued for “Method for Reducing Post-Operative Cognitive Dysfunction (POCD)” Notice of Allowance Issued for “Method for Reducing Post-Operative Cognitive Dysfunction (POCD)”

Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongo...

Three Anti-TNF Product Candidates To Be Included in Expected Global Agreement Three Anti-TNF Product Candidates To Be Included in Expected Global Agreement

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

PALO ALTO, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b clinical trial, fo...

180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement

PALO ALTO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of n...

Why 180 Life Sciences Stock Is Falling Today

Another capital raise less than a year after the company's stock market debut is more than a little troubling.

180 Life Sciences Corp. Announces $15.0 Million Private Placement

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of nov...

180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue

Collaboration Between the Pioneer of Cannabis Chemistry in Israel, Professor Raphi Mechoulam, Sir Marc Feldmann's Laboratory in Oxford, and 180 Life Sciences Scientists, Identifies a Non-Psychoactive Ca...

180 Life Science Corp Nears Key Levels And Could Breakout Soon

180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher Monday after the company announced it regained compliance with the Nasdaq. The company was notified Jan. 6 it did not meet the listing req...

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)

MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of ...